The stock of Immuneering Corp (NASDAQ:IMRX) last traded at $2.00, down -15.25% from the previous session.
IMRX stock price is now -1.39% away from the 50-day moving average and 14.01% away from the 200-day moving average. The market capitalization of the company currently stands at $62.10M.
On March 15, 2024, Needham reiterated its ‘Buy’ rating on the stock by increasing its target price from $20 to quote $15, while ‘TD Cowen’ rates the stock as ‘Market Perform’
In other news, Cormorant Asset Management, LP, 10% Owner sold 400,000 shares of the company’s stock on Apr 01 ’24. The stock was sold for $1,160,181 at an average price of $2.90. Upon completion of the transaction, the 10% Owner now directly owns 2,895,273 shares in the company, valued at $5.79 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 22 ’24, Director Schall Thomas J. bought 2,900 shares of the business’s stock. A total of $7,385 was incurred on buying the stock at an average price of $2.55. This leaves the insider owning 2,900 shares of the company worth $5800.0. A total of 27.87% of the company’s stock is owned by insiders.
During the past 12 months, Immuneering Corp has had a low of $1.00 and a high of $7.68. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 7.99, and a quick ratio of 7.99. The fifty day moving average price for IMRX is $2.0283 and a two-hundred day moving average price translates $1.757 for the stock.
The latest earnings results from Immuneering Corp (NASDAQ: IMRX) was released for 2024-06-30.
